Online inquiry

IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ221MR)

This product GTTS-WQ221MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ221MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15679MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ1334MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ6636MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ8637MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ5805MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ7510MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ4600MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ1194MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW